| Metastatic Colorectal Cancer |
1 |
1 |
| Biologic Therapy |
0 |
0.99 |
| Colorectal Cancer |
0 |
0.95 |
| Angiogenesis Inhibitors |
0 |
0.74 |
| Humanized Monoclonal Antibody |
0 |
0.72 |
| Hepatocellular Carcinoma |
0 |
0.47 |
| Liver Metastases |
0 |
0.45 |
| Cancer |
0 |
0.42 |
| Metastasis |
0 |
0.4 |
| Targeted Cancer Therapy |
0 |
0.4 |
| Lung Cancer |
0 |
0.37 |
| Chemotherapy |
0 |
0.36 |
| Gastric Cancer |
0 |
0.34 |
| Colon Cancer |
0 |
0.32 |
| Noncolorectal Gastrointestinal Cancer |
0 |
0.32 |
| Toxicology |
0 |
0.29 |
| Genomic Medicine |
0 |
0.28 |
| Refractory |
0 |
0.23 |
| Adverse Effects |
0 |
0.16 |
| Liver |
0 |
0.16 |
| Patient Safety |
0 |
0.15 |
| Geriatrics |
0 |
0.1 |
| Drug Resistance |
0 |
0.07 |
| Epidermal Growth Factor Receptor |
0 |
0.07 |
| Medicare |
0 |
0.07 |
| Quality of Life |
0 |
0.07 |
| Vascular Endothelial Growth Factor |
0 |
0.07 |
| Platelet Count |
0 |
0.06 |